Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23245394

DOI

Indexing Status
Subject indexing assigned by NLM

MeSH
Acute Coronary Syndrome /economics /therapy; Aged; Aged, 80 and over; Anticoagulants /economics; Antithrombins /economics /therapeutic use; Cost-Benefit Analysis; Drug Costs; Female; Heparin /economics; Hirudins /economics; Hospitals, University; Humans; Length of Stay /economics; Male; Middle Aged; Paris; Peptide Fragments /economics /therapeutic use; Percutaneous Coronary Intervention; Platelet Glycoprotein GPIIb-IIIa Complex /antagonists & inhibitors; Prospective Studies; Recombinant Proteins /economics /therapeutic use; Registries; Treatment Outcome

AccessionNumber
22013020964

Date bibliographic record published
10/06/2013